Safety Study of CD-NP in Heart Failure

NCT00557661 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-03-25

No results posted yet for this study

Summary

An open-label study designed to determine the safety, tolerability and pharmacodynamics of CD-NP infusions in heart failure patients.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

CD-NP

24 hr intravenous infusion

Sponsors & Collaborators

  • Nile Therapeutics

    lead INDUSTRY

Principal Investigators

  • Steven Goldsmith, MD · Hennepin County Medical Center, Minneapolis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Completion
2008-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557661 on ClinicalTrials.gov